Arcturus Therapeutics Holdings EBITDA 2011-2026 | ARCT

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Arcturus Therapeutics Holdings

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-73.2 M	-92.1 M	-75.2 M	13.7 M	-202 M	-70.6 M	-24.8 M	-21.2 M	-10.1 M	-25.1 M	-19.6 M	-33 M	-10.3 M	-1.49 M	-3.88 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
13.7 M	-202 M	-43.3 M

Quarterly EBITDA Arcturus Therapeutics Holdings

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-15.7 M	-10.8 M	-	-9.84 M	-20.2 M	-29.5 M	-	-18.5 M	-54.7 M	15.3 M	-	-36.4 M	-21.7 M	-50.2 M	-37.6 M	-53.5 M	-53.4 M	-57.4 M	-31.1 M	-20.7 M	-9.84 M	-9.28 M	-10.8 M	-7.42 M	-372 K	-6.34 M	-	-4.16 M	-9.97 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
15.3 M	-57.4 M	-22.6 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
BioNTech SE BNTX	15.3 B	$ 91.28	0.11 %	$ 27.2 B	Germany
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Akari Therapeutics, Plc AKTX	-21.6 M	$ 3.54	-20.81 %	$ 238 B	Britain
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Alnylam Pharmaceuticals ALNY	557 M	$ 330.34	3.6 %	$ 43.3 B	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	-50.6 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
Evogene Ltd. EVGN	-31 M	$ 0.79	1.22 %	$ 27.9 M	Israel
Atreca BCEL	5.46 M	-	-11.76 %	$ 5.79 M	USA
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
argenx SE ARGX	-349 M	$ 748.25	0.25 %	$ 25 B	Niderland
Завод ДИОД DIOD	85.9 M	-	-	-	Russia
Фармсинтез LIFE	-22.6 M	-	-	-	Russia
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Aptorum Group Limited APM	1.19 M	$ 0.89	-4.33 %	$ 4.85 M	China
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Teligent, Inc. TLGT	48.6 M	-	-13.85 %	$ 16.1 M	USA
AbbVie ABBV	15.8 B	$ 206.69	-1.01 %	$ 366 B	USA
Aquestive Therapeutics AQST	-70.5 M	$ 4.09	-0.97 %	$ 437 M	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Viela Bio, Inc. VIE	-151 M	-	-	$ 2.91 B	USA
AbCellera Biologics ABCL	-199 M	$ 3.39	-3.69 %	$ 1.01 B	Canada
Ardelyx ARDX	-37.9 M	$ 5.97	0.51 %	$ 1.44 B	USA
Genmab A/S GMAB	6.57 B	$ 27.75	0.91 %	$ 17.6 B	Danmark
Cerevel Therapeutics Holdings CERE	-442 M	-	-	$ 7.29 B	USA
Grifols, S.A. GRFS	595 M	$ 8.23	-0.12 %	$ 6.83 B	Spain
Akebia Therapeutics AKBA	24.8 M	$ 1.32	-4.35 %	$ 339 M	USA